Using large scale genetic data to understand cholinergic dysfunction in Alzheimer’s diseases

Cholinesterase inhibitors are the primary drugs currently used for the treatment of Alzheimer’s disease (AD), but the exact mechanism of action is unclear. Gaining a more accurate and comprehensive understanding of cholinergic dysfunction and its underlying mechanisms at early stages of AD is crucial for facilitating the development of timely and more effective treatment strategies.

To use large-scale genetic data to understand the causal relationships between the cholinergic pathway and AD.

This work will facilitate a more comprehensive understanding of the cholinergic system’s role in AD.